Table 8 Injury
From: Benefits and harms of medical cannabis: a scoping review of systematic reviews
Author, year {refid} | Search dates; # databases searched | Funding source | Nstudies | Illness/condition | Intervention/comparator | Outcomes | Conclusions from data | AMSTAR-2 rating |
|---|---|---|---|---|---|---|---|---|
Snedecor, 2013 [29] | To Dec 2011; 5 | Industry | 1 | NP associated with spinal cord injury | I: Synthetic cannabinoids C: Placebo | • NP • All-cause discontinuation | Favors control for NP; no statistically significant different between groups for all-cause discontinuation | CL |
Mehta, 2016 [35] | 2009–Sept 2015; 4 | NR | 2 | Spinal cord injury | I: Plant-derived and Synthetic cannabinoids C: diphenhydramine | • NP • Spastic pain | Reported SBS | L |
Meyer, 2010 [55] | 1980–2008; 4 | NR | 2 | Acquired brain injury | I: Synthetic cannabinoids C: Placebo | • Intercranial pressure • Glasgow outcome scale • Disability rating scale • Mortality rates • Activities of daily living • QoL | Reported SBS | M |
Wheaton, 2009 [76] | Jan 1980 to May 2008; 2 | Non-profit | 2 | Traumatic brain injury | I: Synthetic cannabinoids C: placebo | • Global outcome score (3 and 6 months) | No statistically significant difference between groups | CL |